+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
MALE
ID06122584

Evaluating 18FPSMA-1007 PETCT Imaging Accuracy in Newly Diagnosed High-Risk Prostate Cancer Patients

Led by ABX advanced biochemical compounds GmbH · Updated on 2026-11-04

434

Participants Needed

19

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the diagnostic accuracy of 18FPSMA-1007 PETCT imaging in men newly diagnosed with high-risk or very-high-risk prostate cancer. This phase 3 study focuses on patients with biopsy-confirmed, clinically localized prostate adenocarcinoma who are candidates for curative prostatectomy with extended pelvic lymph node dissection. The goal is to compare PETCT results with tissue histology to assess how well this imaging detects pelvic nodal disease. Participants will receive a single intravenous dose of 18FPSMA-1007, a diagnostic radiopharmaceutical, followed by a PET scan. Prior to this, they must have completed conventional imaging methods like CT or MRI and, if needed, a bone scan. This study includes only one group undergoing this imaging procedure to evaluate its diagnostic performance. During the study, participants will undergo PETCT imaging, and results will be compared with histology obtained 6 to 8 weeks after surgery to measure sensitivity and specificity. Researchers will monitor eligibility, adverse reactions, and adherence to the imaging protocol. The total participation duration extends until after surgery and histological analysis, with the primary outcome measured several weeks post-surgery.

CONDITIONS

Brief Title

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Research Team

A

Alexander Hoepping, Dr.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here